Systemic Capillary Leak SyndromeNCT00936325
Studies in the Pathogenesis of Systemic Capillary Leak Syndrome
An observational study of Systemic Capillary Leak Syndrome, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.
Trial summary
Background: Systemic Capillary Leak Syndrome (SCLS) is a disorder of unknown cause characterized by episodes of life-threatening drop in blood pressure and leakage of fluids into tissues. The outcome from an episode of SCLS may be mild and resolve on its own, or may be severe and result in death. Read more about this study
- Who is it for?
- Ages 1 day to 100 years
- Conditions the study is for
- Systemic Capillary Leak Syndrome
- How many people
- 152 participants
- Where
- 1 siteUnited States
- Study dates
- 24 Aug 2009to not given
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 day to 100 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: primary clinical
- PARTICIPANT INCLUSION CRITERIA:
Subjects with SCLS under 8 years of age are only eligible for components of this protocol that can occur Off Site and samples can be sent to the NIH. All SCLS subjects must be at least 8 years old to participate in any other aspects of this protocol at the NIH.
Subjects with SCLS may enter study while pregnant and remain on study after becoming pregnant. At the discretion of the investigator, some components of this protocol will not occur while subject is pregnant.
Diagnosis or suspected diagnosis of Systemic Capillary Leak Syndrome by a physician or documented history of capillary leak as characterized by one or more of the following:
- Hypotension (systolic blood pressure typically less than 90 mm Hg or diastolic blood pressure less than 60 mm Hg) or associated symptoms of hypotension (e.g., hypotonia [collapse], lightheadedness or syncope, incontinence, increased thirst)
- Laboratory evidence of hemoconcentration (e.g., hemoglobin levels above the normal range [typically greater than17 g/dL], elevated leukocyte counts).
- Clinical evidence of fluid extravasation (e.g. edema) and/or laboratory evidence of protein extravasation such as serum hypoalbuminemia (less than 3.5 g/dL) either chronically or during an acute hypotensive episode. Letter of referral, with copies of pertinent medical history and laboratory studies, from prospective study subject s referring physician. Patients may self-refer, but a letter of referral from primary physician is still required. Willing to donate blood for sample storage to be used for future research. PARTICIPANT INCLUSION CRITERIA FOR THE SUBJECT'S RELATIVES/HEALTHY VOLUNTEERS: Willing to donate blood for sample storage to be used for future research. Relatives must be at least 3 years old. Healthy volunteers must be at least 18 years old. Relatives may be pregnant or become pregnant while participating in this protocol. At the discretion of the investigator, some components of this protocol will not occur while subject is pregnant. No skin biopsies or intradermal testing will be done on pregnant relatives. Bloodwork volumes may be decreased at the discretion of the investigator. Healthy volunteers may not be pregnant. Able to give informed consent. PARTICIPANT EXCLUSION CRITERIA: Presence of conditions which, in the judgment of the investigator or the referring physician, may put the subject at undue risk for travel (including frequent episodes of severe capillary leak, symptoms not preventable by pre-medication, acute infection, severe thrombocytopenia [minimum platelet count of 30,000/(proportionaly)L], or significant cardiovascular disease) Any condition that in the view of the principal investigator would make the subject unsuitable for enrollment in this study, (i.e. medically unstable, unable to provide phlebotomy samples). There is an identified cause for hypotensive episodes and/or tissue swelling. PARTICIPANT EXCLUSION CRITERIA FOR THE SUBJECT'S RELATIVES/HEALTHY VOLUNTEERS: Presence of conditions which in the judgment of the investigator or the referring physician may put the subject at undue risk (i.e. medically unstable, unable to provide phlebotomy samples). Any condition that in the view of the principal investigator would make the subject unsuitable for enrollment in this study (i.e. medically unstable, unable to provide phlebotomy samples).
Trial locations and contacts
1 site in 1 country.
United States1 site
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
About this study
Background:
- Systemic Capillary Leak Syndrome (SCLS) is a disorder of unknown cause characterized by episodes of life-threatening drop in blood pressure and leakage of fluids into tissues. The outcome from an episode of SCLS may be mild and resolve on its own, or may be severe and result in death. Although SCLS likely involves abnormalities in the cells lining blood vessels, the specific cause(s) of this disorder are not known.
- The treatment of choice for an acute SCLS episode is intravenous fluids and drugs such as norepinephrine (adrenaline), which are given to keep blood pressure at a level that will maintain vital organ function. This may be followed by a course of intravenous steroids and IVIG. Currently, there is no cure, but IVIG has been effective in diminishing the frequency and/or intensity of SCLS episodes when given regularly, as long-term effective preventive therapy for many patients who experience recurrent episodes of SCLS.
- This protocol is focused on understanding what causes SCLS with the hope that research findings will lead to the design of safe and more effective treatments.
Read more
Objectives:
- To investigate mechanisms that may cause Systemic Capillary Leak Syndrome.
Eligibility:
- Patients between 16 and older who have been diagnosed with SCLS. Patients who have been diagnosed with SCLS and are between the ages of 7 and 16 may participate off-site, by sending specimens to the NIH. Patients 16 and older who have been diagnosed with SCLS and cannot travel to the NIH may also participate off-site.
- Patients must have a documented history of at least one episode of SCLS with all three of the following documented on at least one occasion: low blood volume, low blood pressure without cause, and evidence of protein leakage during the episode. A letter of a referral from a treating physician is also required.
Design:
- Patients seen on site will be evaluated at the National Institutes of Health (NIH) for approximately 4 to 5 days on an inpatient basis, and will undergo the following procedures:
- Medical history and physical examination.
- Blood samples for evaluation and research purposes, as well as possible genetic testing.
- Apheresis procedure, if needed, to obtain a larger volume of blood cells for research.
- Bone marrow biopsy, if medically indicated.
- Other medically indicated tests, such as skin tests to check for possible allergic reactions.
- Patients who have a capillary leak episode while at NIH will be treated with the standard of care for treating SCLS.
- Patients will be discharged from the protocol 1 year after the NIH visit.
- Patients participating off-site will be asked to collect and send specimens (such as blood) to the NIH for research purposes and evaluation.
- Unaffected Biological relatives of SCLS patients and Unrelated Normal Volunteers may also enroll on the study. Relatives and Normal Volunteers may be asked to provide research samples for the study, such as skin biopsy and research blood specimens.
Read the detailed description
The systemic capillary leak syndrome (SCLS, Clarkson syndrome) is an exceedingly rare disorder of unknown cause characterized by chronic edema or acute transient, severe episodes of hypotension, hypovolemia, and oliguria. Severe edema results from leakage of fluid and macromolecules (200-900 kDa) into tissues. Acute SCLS episodes carry a high morbidity and mortality (25-30%). Fewer than 500 cases have been reported worldwide since 1960, although the disease may be underdiagnosed due to the nonspecific nature of the presenting signs and symptoms and the considerable overlap with other shock syndromes including sepsis, anaphylaxis, and angioedema. Approximately 85% of such individuals have a monoclonal gammopathy of unknown significance (MGUS), but the relationship of this finding to disease pathogenesis is unclear. This protocol will focus on the pathogenesis of SCLS. Subjects with documented episodes of capillary leak will be evaluated in order to correlate both clinical and laboratory features that are typical of SCLS. The goal is to identify biological factors and/or genetic and molecular events that may predispose to SCLS episodes. We plan to enroll up to 270 total subjects in this study, which includes affected subjects, family members, and healthy volunteers. We anticipate that our findings may be a first step toward the development of new targeted therapies.
- Conditions
- Systemic Capillary Leak Syndrome
- Keywords
- SCLS, Natural History, Systemic Capillary Leak Syndrome
- Medical subject headings
- Capillary Leak Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Healthy volunteers | healthy volunteers to act as controls. | |
| Patients with SCLS | patients who have been diagnosed, or are suspected of having systemic capillary leak syndrome. | |
| Relatives | relatives of patients who have systemic capillary leak syndrome. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identify potential causative factors and to explore genetic and/or cellular abnormalities that correlate with clinical features of SCLS.
Identify causative mechanisms of SCLS that will aid in diagnosis and treatment.
Measured: Patients return to NIH as necessary
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2009 (estimated)
- Study start24 Aug 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Systemic Capillary Leak SyndromeStudies of the same condition, open and under way.
- More trials run by National Institute of Allergy and Infectious Diseases (NIAID)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 152 participants (actual)
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Kirk M Druey, M.D., Principal investigator, National Institute of Allergy and Infectious Diseases (NIAID)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00936325
- Sponsor's protocol ID
- 090184
- Other IDs
- 09-I-0184
- Status last verified
- 28 Oct 2024
- First submitted
- 9 Jul 2009
- Last updated
- 30 Oct 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: We would provide raw data from IP included in any publication upon request. Since we are not an interventional clinical trial, this would pertain mainly to observational studies.@@@@@@@@@@@@In general, we include all IPD in the papers themselves.
Publications
Cicardi M, Gardinali M, Bisiani G, Rosti A, Allavena P, Agostoni A. The systemic capillary leak syndrome: appearance of interleukin-2-receptor-positive cells during attacks. Ann Intern Med. 1990 Sep 15;113(6):475-7. doi: 10.7326/0003-4819-113-6-475. No abstract available.
PubMed 2386338Atkinson JP, Waldmann TA, Stein SF, Gelfand JA, Macdonald WJ, Heck LW, Cohen EL, Kaplan AP, Frank MM. Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature. Medicine (Baltimore). 1977 May;56(3):225-39. doi: 10.1097/00005792-197705000-00004.
PubMed 870792CLARKSON B, THOMPSON D, HORWITH M, LUCKEY EH. Cyclical edema and shock due to increased capillary permeability. Am J Med. 1960 Aug;29:193-216. doi: 10.1016/0002-9343(60)90018-8. No abstract available.
PubMed 13693909
Study at a glance
From the registry record, last updated by the sponsor on 30 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Studies in the Pathogenesis of Systemic Capillary Leak Syndrome
- ClinicalTrials.gov ID
- NCT00936325
- Acronym / sponsor ID
- 090184
- Conditions
- Systemic Capillary Leak Syndrome
- Keywords
- SCLS, Natural History, Systemic Capillary Leak Syndrome
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 152 participants (actual)
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)US National Institutes of Health
- Study start
- 24 Aug 2009 (actual)
- First posted
- 10 Jul 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
- Systemic Capillary Leak Syndrome (SCLS) is a disorder of unknown cause characterized by episodes of life-threatening drop in blood pressure and leakage of fluids into tissues. The outcome from an episode of SCLS may be mild and resolve on its own, or may be severe and result in death. Although SCLS likely involves abnormalities in the cells lining blood vessels, the specific cause(s) of this disorder are not known.
- The treatment of choice for an acute SCLS episode is intravenous fluids and drugs such as norepinephrine (adrenaline), which are given to keep blood pressure at a level that will maintain vital organ function. This may be followed by a course of intravenous steroids and IVIG. Currently, there is no cure, but IVIG has been effective in diminishing the frequency and/or intensity of SCLS episodes when given regularly, as long-term effective preventive therapy for many patients who experience recurrent episodes of SCLS.
- This protocol is focused on understanding what causes SCLS with the hope that research findings will lead to the design of safe and more effective treatments.
Objectives:
- To investigate mechanisms that may cause Systemic Capillary Leak Syndrome.
Eligibility:
- Patients between 16 and older who have been diagnosed with SCLS. Patients who have been diagnosed with SCLS and are between the ages of 7 and 16 may participate off-site, by sending specimens to the NIH. Patients 16 and older who have been diagnosed with SCLS and cannot travel to the NIH may also participate off-site.
- Patients must have a documented history of at least one episode of SCLS with all three of the following documented on at least one occasion: low blood volume, low blood pressure without cause, and evidence of protein leakage during the episode. A letter of a referral from a treating physician is also required.
Design:
- Patients seen on site will be evaluated at the National Institutes of Health (NIH) for approximately 4 to 5 days on an inpatient basis, and will undergo the following procedures:
- Medical history and physical examination.
- Blood samples for evaluation and research purposes, as well as possible genetic testing.
- Apheresis procedure, if needed, to obtain a larger volume of blood cells for research.
- Bone marrow biopsy, if medically indicated.
- Other medically indicated tests, such as skin tests to check for possible allergic reactions.
- Patients who have a capillary leak episode while at NIH will be treated with the standard of care for treating SCLS.
- Patients will be discharged from the protocol 1 year after the NIH visit.
- Patients participating off-site will be asked to collect and send specimens (such as blood) to the NIH for research purposes and evaluation.
- Unaffected Biological relatives of SCLS patients and Unrelated Normal Volunteers may also enroll on the study. Relatives and Normal Volunteers may be asked to provide research samples for the study, such as skin biopsy and research blood specimens.
Detailed description
The systemic capillary leak syndrome (SCLS, Clarkson syndrome) is an exceedingly rare disorder of unknown cause characterized by chronic edema or acute transient, severe episodes of hypotension, hypovolemia, and oliguria. Severe edema results from leakage of fluid and macromolecules (200-900 kDa) into tissues. Acute SCLS episodes carry a high morbidity and mortality (25-30%). Fewer than 500 cases have been reported worldwide since 1960, although the disease may be underdiagnosed due to the nonspecific nature of the presenting signs and symptoms and the considerable overlap with other shock syndromes including sepsis, anaphylaxis, and angioedema. Approximately 85% of such individuals have a monoclonal gammopathy of unknown significance (MGUS), but the relationship of this finding to disease pathogenesis is unclear. This protocol will focus on the pathogenesis of SCLS. Subjects with documented episodes of capillary leak will be evaluated in order to correlate both clinical and laboratory features that are typical of SCLS. The goal is to identify biological factors and/or genetic and molecular events that may predispose to SCLS episodes. We plan to enroll up to 270 total subjects in this study, which includes affected subjects, family members, and healthy volunteers. We anticipate that our findings may be a first step toward the development of new targeted therapies.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Healthy volunteers | – | –healthy volunteers to act as controls. |
| Patients with SCLS | – | –patients who have been diagnosed, or are suspected of having systemic capillary leak syndrome. |
| Relatives | – | –relatives of patients who have systemic capillary leak syndrome. |
Who may qualify
- Ages
- 1 day to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- primary clinical
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Identify potential causative factors and to explore genetic and/or cellular abnormalities that correlate with clinical features of SCLS.
Time frame: Patients return to NIH as necessary
Identify causative mechanisms of SCLS that will aid in diagnosis and treatment.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2024.
- Background: PubMed 2386338Cicardi M, Gardinali M, Bisiani G, Rosti A, Allavena P, Agostoni A. The systemic capillary leak syndrome: appearance of interleukin-2-receptor-positive cells during attacks. Ann Intern Med. 1990 Sep 15;113(6):475-7. doi: 10.7326/0003-4819-113-6-475. No abstract available.
- Background: PubMed 870792Atkinson JP, Waldmann TA, Stein SF, Gelfand JA, Macdonald WJ, Heck LW, Cohen EL, Kaplan AP, Frank MM. Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature. Medicine (Baltimore). 1977 May;56(3):225-39. doi: 10.1097/00005792-197705000-00004.
- Background: PubMed 13693909CLARKSON B, THOMPSON D, HORWITH M, LUCKEY EH. Cyclical edema and shock due to increased capillary permeability. Am J Med. 1960 Aug;29:193-216. doi: 10.1016/0002-9343(60)90018-8. No abstract available.
- NIH Clinical Center Detailed Web PageLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. We would provide raw data from IP included in any publication upon request. Since we are not an interventional clinical trial, this would pertain mainly to observational studies.@@@@@@@@@@@@In general, we include all IPD in the papers themselves.
Related trials for Systemic Capillary Leak Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kirk M Druey, M.D. principal investigator
National Institute of Allergy and Infectious Diseases (NIAID)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Systemic Capillary Leak Syndrome, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identify potential causative factors and to explore genetic and/or cellular abnormalities that correlate with clinical features of SCLS. (time frame: Patients return to NIH as necessary). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00936325, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2024.